Butorphanol Nasal Spray CIV
Generic Name and Formulations:
Butorphanol tartrate 1mg/spray; nasal spray.
Various generic manufacturers
Indications for Butorphanol Nasal Spray:
Pain management when opioid analgesia is appropriate.
≥18 years: initially 1 spray in 1 nostril, repeat after 60–90 minutes if needed (Elderly: 90–120 minutes); may repeat in 3–4 hours. Or, may give 1 spray in each nostril, may repeat after 3–4 hours.
<18 years: not recommended.
Head injury. Increased intracranial pressure. Biliary tract surgery. Respiratory, cardiac, renal, or hepatic dysfunction. MI. Ventricular dysfunction. Coronary insufficiency. Hypertension. May precipitate withdrawal in narcotic addicts. Elderly. Labor & delivery. Pregnancy (Cat.C). Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Nasal vasoconstrictors delay onset. May be antagonized by concomitant (within 30 minutes) sumatriptan nasal spray.
Sedation, dizziness, nasal congestion, insomnia, GI upset, respiratory depression, sweating, hypo- or hypertension, rash, vasodilation, palpitation, tinnitus, respiratory and CNS effects.
Formerly known under the brand name Stadol NS.
Nasal Spray 2.5mL (8–15 sprays)—Contact supplier.
Neurology Advisor Articles
- Case Study Report: Herbal Supplement Kratom Associated With Neonatal Abstinence Syndrome
- Seizure Monitoring Smartwatch Cleared for Use in Children
- Ocrelizumab Reduces Upper Extremity Disability Progression Risk in PPMS
- Steps to Facilitate Rapid Reperfusion to Improve Poststroke Outcomes
- Cerebellar Stimulation May Help Improve Gait and Balance Recovery in Stroke
- Very Early Mobilization After Stroke Does Not Improve Survival Over Usual Care
- Alemtuzumab Linked to Clinical and MRI Disease Remission in Multiple Sclerosis
- Cognitive Decline Worsens With Memantine, ChEIs in Patients With Alzheimer's
- Cervical Dysfunction Needs Clarification to Identify Link With Headache
- Levodopa Inhalation Powder Approved for Parkinson Disease
- Risk for Conversion of MS Varies With Different Therapies
- Breakdown of Blood-Brain Barrier May Drive Dementia
- FDA: Food Inspections to Resume Despite Ongoing Funding Lapse
- First Generic Version of Sabril Tablets Gets FDA Approval
- Supine Positioning After Greater Occipital Nerve Block May Improve Outcomes